Protagonist Therapeutics Inc

NASDAQ:PTGX   10:50:54 AM EDT
9.21
+0.13 (+1.43%)
Products

Protagonist Therapeutics To Present Updated Phase 2 Rusfertide Clinical Results In Polycythemia Vera (Pv) At Asco 2022

Published: 05/27/2022 00:02 GMT
Protagonist Therapeutics Inc (PTGX) - Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (pv) at Asco 2022.
Protagonist Therapeutics - Enrollment Completed and Dosing Resumed in Ongoing Phase 2 Revive Study.
Protagonist Therapeutics - Resumption of Rusfertide Administration After Suspension Restored Therapeutic Benefits Including Hematocrit Control.
Protagonist Therapeutics - New Data Showed Treatment Suspension in Pv Patients Led to Increases in Hematocrit Levels, Rbc Count, and Phlebotomy Rates.